Vaxart(US:VXRT) Globenewswire·2025-05-05 12:00Core Viewpoint - Vaxart, Inc. is urging stockholders to vote in favor of a reverse stock split proposal to maintain its Nasdaq listing and support ongoing vaccine development efforts [1][9][11] Recent Developments - A government stop work order was lifted on April 24, 2025, allowing Vaxart to proceed with its COVID-19 vaccine clinical trial, which is expected to secure non-dilutive government funding [3] - The company has completed enrollment for its norovirus program, with topline data anticipated in mid-2025, which could attract strategic partnerships and additional funding [4] Strategic Measures - Vaxart is implementing cost control measures, including workforce reductions, to extend its cash runway into 2026 while balancing cost savings with R&D investments [5] - The company is actively seeking additional sources of non-dilutive funding to support its initiatives [5] Stockholder Communication - Vaxart acknowledges stockholder concerns regarding stock performance and emphasizes the importance of compliance with SEC regulations in its communications [6] - The company will host a Q1 2025 earnings call on May 13, 2025, to provide updates and address stockholder questions [7] - A webcast presentation at the Citizens Life Sciences Conference on May 7, 2025, will also be available for stockholders [8] Reverse Stock Split Proposal - The reverse stock split proposal is aimed at preventing delisting from Nasdaq due to a minimum bid price requirement of $1.00 per share, with recommendations from leading proxy advisors to vote "FOR" the proposal [9][10] - The board intends to implement a reverse stock split only if necessary to maintain Nasdaq compliance, preferring to achieve compliance through stock price appreciation [10][11] Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines, including candidates for COVID-19, norovirus, and HPV, utilizing a proprietary delivery platform [13]